Logo

Suggestions

  • Cancer Disparities
  • Opinion
  • Conferences
  • News
  • Patient Corner
  • About
    • Contact
    • Article Submission
  • Top Headlines
    • Cancer Types
      • Breast Cancer
      • Cervical Cancer
      • GI Malignancies
      • Melanoma & Skin Cancer
      • GU Malignancies
      • Gynecologic Oncology
      • Hematologic Malignancies
      • Lung Cancer
  • Expert Opinion
  • Video News
  • New Approvals
  • Cancer Disparities
  • Patient Corner
  • Subscribe

Logo

multiple myeloma

February 27, 2023
Hematologic Malignancies/Opinion

Multicenter Real-World Study Shows Comparable Safety and Efficacy of Ide-Cel in Patients with Relapsed/Refractory Multiple Myeloma

By Dr. Richa Parikh Karmanos Cancer Institute & Dr. Harsh Parmar Hackensack Meridian Health   A multicenter retrospective study, which was conducted at 11 academic centers across the United States, reported a

Hematologic Malignancies/Opinion

KRD Maintenance: Another Alternative for Newly Diagnosed Multiple Myeloma?

By Dr. Harsh Parmar Hackensack Meridian Health   In an unplanned interim analysis of an international phase-III trial (ATLAS) by Dytfeld et al., performed across 12 centers in Poland and the US, data for the efficacy of maintenance therapy with

February 17, 2023

FDA Approves Talquetamab-Tgvs For Adults with Relapsed Or Refractory Multiple Myeloma Patients with at least Four Prior Lines of Therapy

New Approvals/New Drug Applications

By Dr. Anish Shah Bronx Lebanon Hospital   On August 9, 2023, the U.S. Food and Drug Administration approved talquetamab-tgvs (Talvey, Janssen Biotech, Inc.)

FDA Approves Elranatamab-bcmm for Multiple Myeloma with Relapsed or Refractory Status

New Approvals/New Drug Applications

By Dr. Anish Shah Bronx-Lebanon Hospital   On August 14, 2023, the U.S. Food and Drug Administration granted accelerated approval to Elranatamab-bcmm (Elrexfio) for

FDA_Approved
New Approvals/New Drug Applications

FDA Approves Elranatamab-bcmm for Multiple Myeloma with Relapsed or Refractory Status

By Dr. Anish Shah Bronx-Lebanon Hospital   On August 14, 2023, the U.S. Food and Drug Administration granted accelerated approval to Elranatamab-bcmm (Elrexfio) for adults with relapsed or refractory multiple myeloma who

More
by Staff Writer - The Cancer News
August 17, 2023
FDA_Approved
New Approvals/New Drug Applications

FDA Approves Talquetamab-Tgvs For Adults with Relapsed Or Refractory Multiple Myeloma Patients with at least Four Prior Lines of Therapy

By Dr. Anish Shah Bronx Lebanon Hospital   On August 9, 2023, the U.S. Food and Drug Administration approved talquetamab-tgvs (Talvey, Janssen Biotech, Inc.) for adults with multiple myeloma with relapsed or

More
by Staff Writer - The Cancer News
August 14, 2023
Hematologic Malignancies/Opinion

Multicenter Real-World Study Shows Comparable Safety and Efficacy of Ide-Cel in Patients with Relapsed/Refractory Multiple Myeloma

By Dr. Richa Parikh Karmanos Cancer Institute & Dr. Harsh Parmar Hackensack Meridian Health   A multicenter retrospective study, which was conducted at 11 academic centers across the United States, reported a

More
by Staff Writer - The Cancer News
February 27, 2023
Hematologic Malignancies/Opinion

KRD Maintenance: Another Alternative for Newly Diagnosed Multiple Myeloma?

By Dr. Harsh Parmar Hackensack Meridian Health   In an unplanned interim analysis of an international phase-III trial (ATLAS) by Dytfeld et al., performed across 12 centers in Poland and the US,

More
by Staff Writer - The Cancer News
February 17, 2023

your advertisement here

you may also like...

  • targeted-therapy
    Antibody Drug Conjugates
  • FDA_Approved
    FDA Approves Luspatercept-aamt for Anemia in Patients with Myelodysplastic Syndromes
  • hodgkin-lymphoma
    KEYNOTE-087: Pembrolizumab Monotherapy for Relapsed/Refractory Classical Hodgkin lymphoma
  • Overview of KEYNOTE-671 & NADIM II
  • Expert Opinion: Children’s Oncology Group AALL1331: Phase III Trial of Blinatumomab in Children, Adolescents, and Young Adults With Low-Risk B-Cell ALL in First Relapse

All Categories

  • Awareness
  • Breast Cancer
  • Cancer Disparities
  • Cancer Research
  • Conference 2023
  • Conference Coverage
  • Conferences
  • Events
  • GI Malignancies
  • GU Malignancies
  • Hematologic Malignancies
  • Journal
  • Lung Cancer
  • Melanoma & Skin Cancer
  • Nepal Cancer Center
  • New Approvals
  • New Drug Applications
  • News
  • Opinion
  • Patient Corner
  • Spotlights
  • Uncategorized
  • Updates
  • Video News
  • Volunteer Spotlight

Search By Keyword

ASCO ASCO23 award Binaytara foundation breast cancer BTF cancer cancer care cancer disparities cancer research cancer survival cancer treatment Cellular therapy CME conference Conferences continuing education Dr. Binay Shah Dr Anish Shah Dr Shipra Gandhi Expert Opinion faculty highlight FDA FDA Approval FDA approved head & neck cancer surgery in Nepal healthcare equity hematological malignancies hematologic malignancies leukemia Lung cancer lymphoma multiple myeloma Nepal cancer care oncology CME SCHD video news Volunteer

We Transform Cancer Care

Dissect complex information on cancer and disseminate knowledge to healthcare professionals, patients, and caregivers. We want to improve patient outcomes.
Cover the latest research to promote precision oncology and patient-centered care.
Questions? Contact us -
[email protected]

Social Media

Advertisement


Footer Logo
  • Facebook
  • Twitter
  • LinkedIn

© 2023 - All Rights Reserved. Binaytara Foundation

  • About
  • Submit an Article
  • Subscribe for updates
  • Editorial Board
  • Privacy Policy
  • Contact
  • Home
  • Top Headlines
    • Awareness
    • Video News
    • Cancer Types
      • Breast Cancer
      • Cervical Cancer
      • Melanoma & Skin Cancer
      • GI Malignancies
      • Lung Cancer
      • Hematologic Malignancies
      • Gynecologic Oncology
      • GU Malignancies
  • New in Cancer Care
  • Conferences
    • Hemotology & Oncology Conference Calendar
    • Conference Calendar
    • Conference Coverage
  • New Approvals
  • Contact us
  • Submit an article